Michelle Hermiston, MD., PhD.
College of Health Sciences
Professor
Vice Dean, Health Research
Biography
Dr. Michelle L. Hermiston is a Professor of Pediatrics at the University of California, San Francisco (UCSF). Her research focuses on improving the outcomes for children, adolescents, and young adults with leukemia, lymphoma, and histiocytic disorders. She earned her B.S. at the University of Iowa and her MD and PhD degrees at Washington University School of Medicine and the Division of Biology and Biomedical Sciences. She completed a residency in General Pediatrics and a fellowship in Pediatric Hematology and Oncology at UCSF before joining the faculty in 2003. At UCSF, she developed and lead the UCSF Pediatric Immunotherapy Program, serves as Associate Director of the Helen Diller Comprehensive Cancer Center Global Cancer Program (GCP). She helped lead development of the first ever Ministry of Health approved training program in Pediatric Hematology-Oncology at University of Medicine and Pharmacy in Ho Chi Minh, which launched in 2019 and is now training it’s 6th cohort. In her role with the UCSF GCP, she has established Memorandums of Understanding (MOU) with all hospitals caring for children with blood diseases and cancer in Vietnam. Nationally, she is one of the founding members of the North American Consortium for Histiocytoses (NACHO), currently chairs the Histiocyte Society Langerhans Cell Histiocytosis Committee, and is Vice Chair for the Children’s Oncology Group Non Hodgkin Lymphoma Steering Committee and Chair of the NHL Biology committee where she participates in development and implementation of clinical trials. She also serves as Educational Advisor for the Society International Oncology Pediatrica (SIOP) – North America. Additionally, she has served as an Adjunct Professor of Pediatrics at VinUniversity in Hanoi, Vietnam since 2022. She will be joining VinUniversity as the first Vice Dean of Health Research in the College of Health Sciences in November, 2024.
• Leukemia and lymphoma
• Histiocytic disorders
• Translational and clinical research
• Novel pedagogical approaches to developing an Inquiry Habit of Mind
• Implementation science
• Building equitable partners in global pediatric cancer
• Pediatric hematology and oncology
• Clinical trials
• Professional development and leadershi
1. Hermiston ML, Gordon JI. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science. 1995 Nov 17; 270(5239):1203-7. PMID: 7502046
2. Hermiston ML, Wong MH, Gordon JI. Forced expression of E-cadherin in the mouse intestinal epithelium slows cell migration and provides evidence for nonautonomous regulation of cell fate in a self-renewing system. Genes Dev. 1996 Apr 15; 10(8):985-96. PMID: 8608945 Selected for cover.
3. Hermiston ML, Tan AL, Gupta VA, Majeti R, Weiss A. The juxtamembrane wedge negatively regulates CD45 function in B cells. Immunity. 2005 Dec; 23(6):635-47. PMID: 16356861
4. Mills RE, Lam VC, Tan A, Cresalia N, Oksenberg N, Zikherman J, Anderson M, Weiss A, Hermiston ML. Unbiased Modifier Screen Reveals That Signal Strength Determines the Regulatory Role Murine TLR9 Plays in Autoantibody Production. J Immunol. 2015 Apr 15; 194(8):3675-86. PMID: 25769918
5. Delgado-Martin C, Meyer LK, Huang BJ, Shimano KA, Zinter MS, Nguyen JV, Smith GA, Taunton J, Winter SS, Roderick JR, Kelliher MA, Horton TM, Wood BL, Teachey D, Hermiston ML. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. Leukemia. 2017 May 09. PMID: 28484265
6. Meyer LK, Huang BJ, Delgado-Martin C, Roy RP, Hechmer A, Wandler AM, Vincent TL, Fortina P, Olshen AB, Wood BL, Horton TM, Shannon KM, Teachey DT, Hermiston ML. Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes. J Clin Invest. 2020 Feb 03; 130(2):863-876. PMID: 31687977. PMCID: PMC6994137
7. Si Lim S, Ford JB, Hermiston ML. How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults. Blood. 2023 Apr 05. PMID: 37018730
8. El-Mallawany NK, Alexander S, Fluchel M, Hayashi RJ, Lowe EJ, Giulino-Roth L, Wistinghausen B, Hermiston M, Allen CE, COG NHL Committee. Children’s Oncology Group’s 2023 blueprint for research: Non-Hodgkin lymphoma. Pediatr Blood Cancer. 2023 Jul 14; e30565. PMID: 37449925
| 1984 – 1988 | University of Iowa | B.S. with Honors | Exercise Physiology | |
| 1989 – 1997 | Washington University | M.D. | ||
| 1989 – 1997 | Washington University | Ph.D. | Biology/Biomedical Sciences: Developmental Biology | Jeffrey Gordon, MD |
| 1997 – 1999 | University of California San Francisco | Resident | Pediatrics | |
| 1999 – 2003 | University of California San Francisco | Clinical Fellow | Pediatric Hematology/Oncology | |
| 2000 – 2007 | University of California, San Francisco | Post-doctoral Fellow | Immunology | Arthur Weiss, MD, PhD |
| 2019 – 2019 | University of California, San Francisco | Diversity, Equity, and Inclusion Champion Training | ||
| 2017 – 2022 | University of California, San Francisco | Teach for UCSF Certificate in Education Leadership | ||
| 2020 | University of California, San Francisco | UCSF Implementation Science Workshop |
Alpha Omega Alpha Honor Society, American Medical Women’s Associate Janet M. Glasgow Award (to women graduating in the top 10% of their class), St. Baldrick Association Career Development Award, NCI K08 Mentored Physician Scientist Training Award, UCSF Exceptional Physician Award Honorable Mention, UCSF Academy of Medical Educators Excellence in Teaching Award, UCSF John L. Ziegler Outstanding Mentor Awar
